Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04432207 · ClinicalTrials.gov registry record · Phase 1
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Imugene Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04432207: Clinical Trial Phase 1 study, sponsored by Imugene Limited.
NCT04432207 is a Phase 1 study that was terminated before completion, run by Imugene Limited. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04432207, a Phase 1 study, was terminated before completion, sponsored by Imugene Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter).
Primary Outcome
Safety and Tolerability Measures include: Frequency of adverse events (AEs) graded per terminology criteria for adverse events (CTCAE) version 5.00.
Interventions
- DRUG Atezolizumab
- BIOLOGICAL IMU-201 (administered as PD1-Vaxx) - Regimen 1
- BIOLOGICAL IMU-201 (administered as PD1-Vaxx) - Regimen 2
- BIOLOGICAL IMU-201 (administered as PD1-Vaxx) - Regimen 3
- DRUG Standard of care chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Why NCT04432207 stopped before completion
NCT04432207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04432207 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04432207 about?
NCT04432207 is a clinical study titled "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer". An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter).
What is the current status of trial NCT04432207?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-11-30. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT04432207?
The interventions under investigation include: Atezolizumab (DRUG), IMU-201 (administered as PD1-Vaxx) - Regimen 1 (BIOLOGICAL), IMU-201 (administered as PD1-Vaxx) - Regimen 2 (BIOLOGICAL), IMU-201 (administered as PD1-Vaxx) - Regimen 3 (BIOLOGICAL), Standard of care chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04432207?
This trial is sponsored by Imugene Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04432207's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI